TGM2 and diabetes mellitus: Here, we show a significant reduction of TG2 activity associated with G3C12‐NTIMP3 peptide treatment during diabetes; however, the link between TIMP3 and TG2 should be more investigated to evaluate if TIMP3 may control, directly or through the regulation of its targets, the activity of TG2, thus modulating kidney fibrosis.